Marc Hoffmann

1.5k total citations
58 papers, 428 citations indexed

About

Marc Hoffmann is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Marc Hoffmann has authored 58 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 21 papers in Pathology and Forensic Medicine and 18 papers in Genetics. Recurrent topics in Marc Hoffmann's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (17 papers) and CAR-T cell therapy research (16 papers). Marc Hoffmann is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (17 papers) and CAR-T cell therapy research (16 papers). Marc Hoffmann collaborates with scholars based in United States, Poland and France. Marc Hoffmann's co-authors include Javier Muñoz, Ramanan Laxminarayan, Michael R. Eber, Nausheen Ahmed, Steve Arcona, Al‐Ola Abdallah, Chris L. Pashos, Patrick Cobb, Bradley D. Hunter and Qin Wang and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marc Hoffmann

49 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Hoffmann United States	10	209	106	77	65	59	58	428
Maged I. Gharib United Kingdom	7	102 0.5×	59 0.6×	61 0.8×	85 1.3×	30 0.5×	10	382
Masatoshi Sakurai Japan	13	118 0.6×	39 0.4×	105 1.4×	204 3.1×	114 1.9×	69	497
Yufeng Shang China	10	108 0.5×	42 0.4×	131 1.7×	46 0.7×	52 0.9×	30	443
Tianyou Wang China	13	85 0.4×	35 0.3×	94 1.2×	41 0.6×	36 0.6×	62	468
Jutta K. Neuenburg United States	10	163 0.8×	216 2.0×	166 2.2×	34 0.5×	150 2.5×	27	649
Sung-Nam Lim South Korea	9	80 0.4×	79 0.7×	43 0.6×	100 1.5×	41 0.7×	36	262
Farhad Khimani United States	12	457 2.2×	206 1.9×	106 1.4×	128 2.0×	48 0.8×	67	741
Rafał Watrowski Germany	15	145 0.7×	39 0.4×	127 1.6×	27 0.4×	11 0.2×	56	616
Seema Naik United States	9	192 0.9×	44 0.4×	72 0.9×	96 1.5×	58 1.0×	48	365
Suheil Albert Atallah‐Yunes United States	8	172 0.8×	52 0.5×	42 0.5×	26 0.4×	34 0.6×	22	305

Countries citing papers authored by Marc Hoffmann

Since Specialization

Citations

This map shows the geographic impact of Marc Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Hoffmann more than expected).

Fields of papers citing papers by Marc Hoffmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Hoffmann. The network helps show where Marc Hoffmann may publish in the future.

Co-authorship network of co-authors of Marc Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Hoffmann. A scholar is included among the top collaborators of Marc Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Hoffmann. Marc Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2025). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 26(2). 200–213. 9 indexed citations

Davis, James A., et al.. (2024). Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb). Blood. 144(Supplement 1). 2350–2350. 2 indexed citations

Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations

Hoffmann, Marc, Theodoros P. Vassilakopoulos, Javier Muñoz, et al.. (2024). Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma. Blood. 144(Supplement 1). 1742.2–1742.2. 1 indexed citations

Jurczak, Wojciech, Michael Wang, Marek Trněný, et al.. (2024). Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study. Clinical Lymphoma Myeloma & Leukemia. 24. S226–S226.

Stephens, Deborah M., Chris Stewart, Catherine C. Coombs, et al.. (2024). Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey. Blood. 144(Supplement 1). 7743–7743.

Hoffmann, Marc, et al.. (2024). Rare presentation and unconventional treatment of Rosai–Dorfman disease. BMJ Case Reports. 17(10). e262184–e262184.

Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 142(Supplement 2). LBA–2. 13 indexed citations

Ahmed, Nausheen, James A. Davis, Leyla Shune, et al.. (2023). Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias. European Journal Of Haematology. 112(4). 538–546. 8 indexed citations

10.

Olszewski, Adam J., Tycel Phillips, Marc Hoffmann, et al.. (2023). Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Advances. 7(20). 6055–6065. 24 indexed citations

11.

Ahmed, Nausheen, Moazzam Shahzad, Ernie Shippey, et al.. (2022). Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplantation and Cellular Therapy. 28(7). 358–364. 77 indexed citations

12.

Hoffmann, Marc & Siddhartha Ganguly. (2021). Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy. Clinical Lymphoma Myeloma & Leukemia. 21(6). e548–e550. 9 indexed citations

13.

Bennett, Joseph, et al.. (2020). Immune Thrombocytopenia Purpura Secondary to COVID-19. Cureus. 12(7). e9083–e9083. 19 indexed citations

14.

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2018). Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1018–1018. 21 indexed citations

15.

Hoffmann, Marc, Michael J. Overman, & Joseph L. Nates. (2016). Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine in a patient with pancreatic cancer. The Journal of Community and Supportive Oncology. 14(4). 178–179. 1 indexed citations

16.

Geethakumari, Praveen Ramakrishnan, Marc Hoffmann, Naveen Pemmaraju, et al.. (2014). Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. Clinical Lymphoma Myeloma & Leukemia. 14(4). e115–e118. 19 indexed citations

17.

Lee, Won Chan, Marc Hoffmann, Steve Arcona, et al.. (2005). A cost comparison of alternative regimens fortreatment-refractory partial seizure disorder: An econometric analysis. Clinical Therapeutics. 27(10). 1629–1638. 8 indexed citations

18.

Lee, Won Chan, Steve Arcona, Simu K. Thomas, et al.. (2005). Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder. Epilepsy & Behavior. 7(1). 123–126. 36 indexed citations

19.

Fauser, A. A., M. Fellhauer, Marc Hoffmann, et al.. (1999). Guidelines for anti-emetic therapy: acute emesis. European Journal of Cancer. 35(3). 361–370. 23 indexed citations

20.

Gebhart, E., et al.. (1993). Cytogenetic studies in lymphocytes of patients with rectal cancer.. Environmental Health Perspectives. 101(suppl 3). 169–175. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact